Abstract-Quantifying myocardial fibrosis (MF) with myocardial extracellular volume measures acquired during cardiovascular magnetic resonance promises to transform clinical care by advancing pathophysiologic understanding and fostering novel therapeutics. Extracellular volume quantifies MF by measuring the extracellular compartment depicted by the myocardial uptake of contrast relative to plasma. MF is a key domain of dysfunctional but viable myocardium among others (eg, microvascular dysfunction and cardiomyocyte/mitochondrial dysfunction). Although anatomically distinct, these domains may functionally interact. MF represents pathological remodeling in the heart associated with cardiac dysfunction and adverse outcomes likely mediated by interactions with the microvasculature and the cardiomyocyte. Reversal of MF improves key measures of cardiac dysfunction, so reversal of MF represents a likely mechanism for improved outcomes. Instead of characterizing the myocardium as homogenous tissue and using important yet still generic descriptors, such as thickness (hypertrophy) and function (diastolic or systolic), which lack mechanistic specificity, paradigms of cardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on the extent of disease involving its various compartments. Specifying myocardial compartmental involvement may then implicate cellular/molecular disease pathways for treatment and targeted pharmaceutical development and above all highlight the role of the cardiac-specific pathology in heart failure among myriad other changes in the heart and beyond. The cardiology community now requires phase 2 and 3 clinical trials to examine strategies for the regression/prevention of MF and eventually biomarkers to identify MF without reliance on cardiovascular magnetic resonance. It seems likely that efficacious antifibrotic therapy will improve outcomes, but definitive data are needed. (Circ Cardiovasc Imaging.
Q uantifying myocardial fibrosis (MF) with routine myocardial extracellular volume (ECV) measures acquired during cardiovascular magnetic resonance (CMR) introduces an exciting era in cardiology that ultimately promises to transform clinical care by advancing pathophysiologic understanding and fostering novel therapeutics. Investigators define MF, also termed reactive interstitial fibrosis, as an increase in interstitial collagen concentration that represents pathological structural remodeling in noninfarcted myocardium. 1, 2 Among myriad multiorgan signaling cascades occurring in heart disease, quantifying MF highlights a critical abnormality that is cardiac specific. [3] [4] [5] MF represents a key component of dysfunctional but viable myocardium-indeed salvageable myocardium-among other myocardial domains including microvascular disease and cardiomyocyte/mitochondrial dysfunction. Although anatomically distinct, these domains may functionally interact with each other.
MF can affect microvascular function, mechanical function, electric function, and myocyte energetics, 6 reflecting several deleterious cardiomyocyte-extracellular matrix interactions beyond the interstitium discussed later. These ECV for Novel Therapeutics abnormalities may culminate in adverse outcomes. [7] [8] [9] [10] [11] [12] [13] Reversal of MF improves key domains of cardiac dysfunction parameters, [14] [15] [16] [17] [18] so reversal of MF represents a likely mechanism for improved outcomes as well. 19 Indeed, dysfunctional myocardium often may be salvageable in the absence of large amounts of focal myocardial scarring, and some think there is enormous, untapped cardiac reserve in most hearts.
Novel noninvasive techniques now permit routine evaluation of MF that was previously limited to myocardial biopsy or postmortem examinations. Historically, the impracticality of quantifying or even detecting MF obscured its biological relevance, leading to its relegation as a secondary phenomenon after cardiomyocyte damage. 20 Nonetheless, quantifying MF with noninvasive metrics such as myocardial ECV measures acquired during routine CMR or even computed tomography (CT) scanning introduces an exciting era in cardiology that ultimately promises to transform clinical care. The scenario is analogous to enabling a mechanic to inspect a car's problematic engine with advanced tools. This review will first discuss the principles of MF measurement in noninfarcted myocardium, the rationale and concepts supporting MF measurement, and then review the implications of such a measurement in the management of cardiac disease and in particular heart failure.
Techniques and Evidence for Noninvasive Assessment of MF
Among various methodologies to quantify MF in noninfarcted myocardium, ECV by CMR seems the most robust because it quantifies the expansion of extracellular compartment where collagen resides. Both ECV and the extracellular compartment increase in proportion to extent of MF. ECV measures by cardiac CT also seem promising, but are less well studied. While native (precontrast) T1 21-26 also increases and postcontrast T1 [23] [24] [25] [27] [28] [29] decreases with MF on CMR scans, they remain inferior MF measures compared with ECV, and the latter is not recommended. 30 For example, several confounders besides MF affect postcontrast T1, such as renal clearance, body weight, anemia, time elapsed after the bolus, and intrinsic contrast agent properties (eg, relaxivity). Similarly, native T1 has less specificity and less sensitivity for MF because native T1 reflects changes related to disease processes involving the whole myocardium, including the intracellular and extracellular compartments or both. Native T1 is also sensitive to many scanner parameters, so its standardization with healthy volunteers is recommended for each individual CMR scanner and each specific T1 protocol. 30 It is important to note that ECV is not a direct measure of interstitial collagen volume fraction but rather a direct measure of the total interstitial space. Of course, the space includes the extracellular matrix primarily composed of type 1 fibrillar collagen. It also includes other fibrillary proteins (elastin), nonfibrillary proteins (eg, aminoglycans, fibronectin, laminin), and bioactive proteins (eg, transforming growth factor-β, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases). 5 ECV measures also include myocardial vasculature in the form of capillaries, as well as other blood elements and fluids. Variation in the microvasculature seems small, 31 and any capillary rarefaction occurring with MF 32 would only diminish ECV measures. Despite ECV's imperfections, a wealth of data support ECV as a robust MF measure in noninfarcted myocardium by CMR. First, ECV is well validated against collagen volume fraction. [23] [24] [25] 29, [33] [34] [35] [36] ECV is highly reproducible across separate CMR scans. 35, [37] [38] [39] [40] [41] [42] ECV can detect clinical reversal of MF. 18 While other measures can correlate with MF, 22, 27, 28 in head-to-head comparisons, ECV almost always remains superior to native [23] [24] [25] 34, 36 or postcontrast T1 23, 25, 26, 29, 36 in terms of agreement with collagen volume fraction and superior to native T1 43 or postcontrast T1 43 for predicting outcomes in large cohorts. Inferred functional measures of MF inherently lack specificity, reflecting either interstitial or cardiomyocyte abnormalities or both, and diastolic Doppler based parameters are notably load dependent. [44] [45] [46] [47] ECV measurement simply uses freely diffusing (ie, nonprotein-bound) extracellular molecules as extracellular space markers. Clinically, ECV measures typically use CMR with gadolinium contrast (Gd) agents, [23] [24] [25] 29, [33] [34] [35] [36] but cardiac CT can also measure ECV with iodinated contrast agents. [48] [49] [50] [51] [52] [53] Table 1 summarizes published histological validation manuscripts for ECV (by CMR of cardiac CT), native T1, and postcontrast T1 specifically using the collagen volume fraction in humans as the gold standard for MF measurement. Conceptually, ECV simply reflects the uptake of the extracellular space marker by the myocardium relative to the plasma based on their relative concentrations, assuming equilibration has occurred between plasma and interstitial fluid. For example, if myocardial Gd concentration is 33% of the plasma Gd concentration after equilibration, the ECV is then 33%, which includes the myocardial microvasculature as well. Because ECV by CMR has generated a significant body of literature, ECV by CMR will be emphasized and explored in detail in this review.
ECV measurement by CMR requires Gd, which disperses rapidly throughout the extracellular fluid in the body after a bolus because of its low molecular weight. After ≈8 minutes, a steady-state equilibrium occurs between plasma and the myocardial interstitial fluid because renal clearance is relatively slow. 23 After equilibration, the proportion of Gd in the myocardium relative to the Gd in the plasma then represents a direct measure of the interstitial space, which remains reasonably constant over time (≈10-30 minutes after contrast). 23, 38, 39, 54 To measure plasma Gd concentration, one must first measure the whole blood Gd concentration from CMR images and then divide the whole blood concentration by (100%−hematocrit) because the hematocrit displaces Gd from the blood pool. Plasma Gd concentration is always higher than the whole blood concentration. If hematocrit data are not acquired, robust synthetic ECV measures still can be generated by estimating the hematocrit from native (precontrast) T1 measures. 55, 56 This important innovation seems robust and renders ECV maps immediately available at the end of the CMR scanning session to facilitate its clinical integration. 55 The principle of estimating hematocrit from precontrast blood pool measures has also been extended to CT. ECV for Novel Therapeutics
The Gd concentration in myocardium and whole blood are determined by measuring the change in relaxivity before and after contrast, where relaxivity R=1/T1. The paramagnetic effects of Gd hasten recovery of magnetization after a radiofrequency pulse (ie, shortens T1, increases R). In general, change in relaxivity (or 1/T1) is linearly related to Gd concentration. ECV exploits this characteristic and is defined as
where the partition coefficient λ=(ΔR1 myocardium )/ (ΔR1 bloodpool ) pre-and post-gadolinium contrast administration (where R1=1/T1). 30 Practically speaking, ECV simply reflects the uptake of Gd relative to the plasma, and the (100%−hematocrit) term accounts for the displacement of Gd by red blood cells. ECV is usually expressed as volume percent.
MF may occur in patients with systemic disease, including renal disease. As such, CT ECV measures may be especially useful for end-stage renal patients on dialysis because Gd is contraindicated in advanced renal disease. Otherwise, these patients are limited to native T1 MF measures. For cardiac CT ECV computation, one can also measure the partition coefficient, λ=ΔHU myocardium /ΔHU bloodpool , where ΔHU change in tissue attenuation before and 10 minutes after iodinated contrast administration. 48 ECV measures require T1 measures often with T1 mapping. T1 simply represents the exponentiated time constant representing the nonlinear recovery of longitudinal magnetization (spin-lattice relaxation) after a radiofrequency pulse. T1 is expressed in units of time (eg, millisecond) and varies with temperature and chemical composition. Practically, one measures T1 by fitting the changes in signal intensity in a series of 24 We rank various myocardial fibrosis measures according to the R 2 value: extracellular volume (ECV) by cardiovascular magnetic resonance (CMR), ECV by cardiac computed tomography (CT), native (precontrast) T1 or post contrast T1. The R 2 value (ie, the square of the correlation coefficient) describes the proportion of variation in collagen volume fraction explained by ECV. Some articles are listed more than once if multiple measures were reported.
T1-weighted images acquired at specified time points after a radiofrequency pulse. The Modified Look Locker inversion 57 using an inversion radiofrequency pulse pioneered by Daniel Messroghli is the most used pulse sequence for myocardial T1 measurement, but other sequences are also available. 38, [58] [59] [60] [61] Their relative merits and feasibility for clinical implementation remain areas of active investigation. 62 Modified Look Locker inversion uses a 3-parameter mathematical model to describe signal intensity (SI) as a function of exponentiated time after a 180° radiofrequency inversion pulse (inversion time, TI):
where T1=T1×((B/A)−1). 63 Important optimizations of this strategy include phase-sensitive reconstruction, 64 which improves fitting of the data by removing a degree of freedom (by ascertaining the polarity of the images) which removes the absolute value signs from the above equation. Motion correction 65 improves coregistration of the component images from which the pixel-wise T1 or ECV maps are derived, improving data quality and facilitating work flow. Associated error maps 66 also reveal acquisition problems (eg, misregistration) or associated artifacts (off resonance), which alert the operator to the need for repeat measurements. These innovations all improve the robustness of the technique and can be extended to ECV mapping. MF can affect microvascular function, mechanical function, electric function, and likely cardiomyocyte energetics, although this latter intuitive assertion is not well studied. 6 Still, these observations involving compartments beyond the interstitium demonstrate cardiomyocyte-extracellular matrix interactions. These interactions include the following:
-Capillary rarefaction and perivascular fibrosis 32 that limit perfusion reserve; 14, 67, 68 -Increased space between the capillary and collagenencircled cardiomyocyte, increasing the oxygen diffusion distance and rendering the cardiomyocyte prone to hypoxia, 69 an important trigger of cardiomyocyte-programmed cell death or apoptosis, 70 potentially promoting progressive MF; -Myocardial stiffening 44, 71 from titin and collagen expansion with increased cross-linking in MF that leads to systolic and diastolic dysfunction 1, 15, 17, 68 and increased filling pressures; 44 -Impaired electric conduction from disarray in the collagen network architecture that predisposes to reentrant arrhythmia and sudden death; 72, 73 -Likely impaired cardiomyocyte/mitochondrial energetics if interposing excess collagen isolates cardiomyocytes from capillaries in the setting of decreased perfusion reserve, arrhythmia, and myocardial stiffening, 74 culminating in an engine out of fuel. 75 A variety of reversibility studies provide even further compelling evidence of deleterious collagen-cardiomyocyte interactions: reversing MF in humans with modestly effective pharmacological therapy targeting the profibrotic reninangiotensin-aldosterone system (RAAS) as shown in Table 2 improves mechanical function, [15] [16] [17] microvascular function, 14 and probably electric function. [76] [77] [78] In animal models, MF is clearly reversible with physical activity, [79] [80] [81] [82] [83] pharmacological therapy, 1, [84] [85] [86] [87] and biological therapy. 88 The heart may be like the liver, lung, and kidney, where accumulation of collagen leads to organ dysfunction and worse outcomes.
The interstitial-cardiomyocyte interactions apparent in the prototypic interstitial heart disease, cardiac amyloidosis (CA), further underscore the potential for MF to promote patient vulnerability through cardiomyocyte interactions. The prognosis in CA is among the worst in cardiac diseases. Large amounts of presumably inert misfolded protein (transthyretin or primary light chain amyloidosis [AL] protein) accumulate in the interstitium-to a much greater extent than MF 35 leading to diastolic and systolic dysfunction through ventricular stiffening, ventricular arrhythmia, and sudden cardiac death, and even ischemia with perfusion deficits in severely affected myocardium. 73 Indeed, higher myocardial ECV predicts worse survival in CA. 89 
Evidence and Gaps for MF Detected by ECV Equating Multiple Cellular and Molecular Derangements
While ECV quantifies the increase in collagen concentration, the complexity of collagen pathophysiology transcends simple ECV estimates of collagen expansion (or even total collagen quantity-estimated by multiplying ECV and total left ventricular mass). MF indicates a complex state of dysregulation of collagen metabolism by cardiac fibroblasts/myofibroblasts where there is excess synthesis or decreased clearance. In this scenario, excess fibrillar collagen (mostly type 1 but also type 3) accumulates in the interstitium, leading to excess concentration of collagen relative to cardiomyocytes. ECV quantifies interstitial expansion in the myocardium but likely represents a surrogate for a fibrotic cascade involving a series of cellular and molecular changes. Differentiation of fibroblasts into metabolically active myofibroblasts represents a key event in MF. 90 Other processes mediated by myofibroblasts, such as collagen cross-linking by the enzyme lysyl oxidase, also occur in MF. Collagen cross-linking stiffens the myocardium and seems prognostically important. 91 Collagen cross-linking diminishes degradation of collagen by matrix metalloproteinases (eg, MMP-1). In addition, titin, a large spring-like cardiomyocyte protein that stiffens with phosphorylation, may also contribute to functional myocardial alterations in MF. Inflammatory cytokines, reactive oxygen species, mast cell-derived proteases, hormones, and growth factors also mediate MF. 92 The complexities of the MF secretome have been reviewed elsewhere. 90, 92 These processes and others likely coexist when ECV measures indicate MF.
Fibroblast regulation remains an understudied area given its apparent biological importance. MF may not occur solely to replace lost myocytes. Investigators have noted a positive correlation between left ventricular mass and MF observed in both pathology [93] [94] [95] [96] and ECV 7 studies. The positive mass-ECV ECV for Novel Therapeutics correlation suggests the potential for a primary role for fibroblast-mediated cardiomyopathy as observed experimentally. 20 Secondary fibroblast activation only in response to cardiomyocyte loss would yield a negative correlation between ECV and left ventricular mass.
Gaps, Challenges, and Limitations of MF Measurement
Because of limited spatial resolution of CMR, partial volume averaging poses a challenge for ECV measures because adjacent tissue (blood and fat) can introduce error. Most centers measure only mid myocardial ECV to avoid partial volume effects, and so subendocardial pathology is excluded by definition. Yet, because ECV is used to quantify diffuse disease, ECV measures remain important. ECV maps permit visualization of partial volume effects by voxels that straddle borders between blood and myocardium (Figure 1 ), which are then avoided during its measurement. During scanning, care must be taken to avoid obliquity and ensure myocardium is perpendicular to the image plane. Obliquity worsens partial volume effects, given relative thick imaging planes with anisotropic voxels. Apical measures are especially challenging because apical myocardium is usually thinner and in the short axis orientation, and obliquity is difficult to avoid because of the conical shape of the apex. Both obliquity and thin walls worsen partial volume effects in the apex. Through-plane motion from respiratory motion especially in the 3-and 4-chamber long-axis orientations may also worsen partial volume effects, and so breath holding is recommended. The 2-chamber orientation has less through-plane motion. Systolic imaging can overcome limitations of T1/ ECV measurement related to arrhythmia and partial volume effects. 97 Refinement of ECV measurements that continue to evolve are reviewed in detail elsewhere in a consensus document 30 undergoing further revision for publication in 2017. Despite the potential for pitfalls in MF measurement, ECV still demonstrates robust risk stratification, confirming its detection of prognostically relevant disease. This strong association with outcomes can be conceptualized as an important positive control for its measurement, demonstrating its ability the ability to stratify risk confirmed by actual adverse events after CMR scanning.
Women seem to have higher ECV than men. 98 Whether this reflects thinner myocardium prone to partial volume error or innate biological differences remains uncertain. Even if biological differences in ECV do exist between men and women, whether the differences reflect heterogeneity in collagen or the myocardial microvasculature is uncertain. Whether any biological differences also translate into increased vulnerability also requires further investigation.
Other Causes of Extracellular Space Expansion
Other confounding conditions besides MF can increase ECV (and also increase native T1 and lower postcontrast T1). These conditions often can be identified by ancillary clinical and imaging data. For example, CA typically involves extensive light chain (AL) or transthyretin protein deposition in the cardiac interstitium. Cardiac amyloidosis often generates higher ECV values (>40%) than MF, and CA has other structural characteristics (eg, increased thickness) and functional characteristics (eg, poor annular motion) that usually render it readily identifiable to the experienced CMR reader, especially on late gadolinium enhancement images. 99 Still, some phenotypic overlap likely exists, which might benefit from either bone scintigraphy scans or serial examinations because CA is a progressive disease.
Diffuse myocardial edema occurs with acute heart failure, which may inflate MF measures because of accumulation of excess water in the interstitial space, but diuresis reverses the myocardial edema. 100 Edema increases native (precontrast) T1 and T2, 101 rendering myocardial edema detectable in the appropriate clinical context. MF itself seems to increase myocardial water content, 21 but the upper limit for physiologically appropriate increases in myocardial water that naturally occur with MF above which designates myocardial edema remains undefined. Some phenotypic overlap undoubtedly exists between MF and edema, but the extent of confounding is likely minor (Erik Schelbert, MD, MS, unpublished data, 2017) because myocardial edema can be suspected by the clinical context and demonstrated on native T1 and T2 Artifacts related to histological processing of tissue can corrupt the histological validation between in vivo MF measures and ex vivo collagen volume fraction measures. The space between cells can increase and become distorted during processing and introduce error in the assessment for the collagen volume fraction. This issue is particularly relevant when myocardial tissue is fixed with formalin. However, many of these difficulties can be obviated by using freshly frozen tissue sections for histological evaluation of collagen volume fraction or total interstitial space. Considering this significant limitation, the ECV and collagen volume fraction validation data seem remarkably robust (Table 1) .
Intrinsic sample errors likely also present a major source of error in histological validation studies. Matching ECV to the sampled myocardium poses challenges. Even though MF is mostly diffuse, considerable spatial variation in the density of MF at the macroscopic level is often apparent of pathology images. For example, there seems to be a subendocardial predilection of MF in ischemic cardiomyopathy, 104 which would not be readily accessible by ECV measures that mostly sample the mid myocardium. Nonetheless, whole heart ECV validation data seem robust, 23 and averaged ECV measures sampling a majority of myocardial segments remain powerful stratifiers of risk, surpassing even ejection fraction. 7 Notably, the capillary rarefaction that occurs with adverse remodeling 32 would only diminish the relationships between MF and ECV because ECV measures include the myocardial microvasculature. Yet, the totality of the histological validation data still favors ECV as the noninvasive MF metric of choice. Concerns about the safety of Gd in advanced renal disease (ie, stage IV or greater) likely limits ECV measures of MF to cardiac CT in this clearly vulnerable patient subpopulation. 
Emerging Applications for the Clinical Management of MF
How best to manage MF remains undefined, reflecting the ignorance arising from the historic challenges in its noninvasive measurement. The scientific community has repeatedly demonstrated associations between MF and vulnerability to adverse events and outcomes. 74 MF clearly exhibits some degree of plasticity and reversibility in animals 20, 88 and humans as well (Table 2) . This problem represents an important opportunity for further investigation. The emerging collective expertise in MF measurement will undoubtedly advance our understanding of MF and how its measurement may ultimately improve patient care. The scientific community finally has robust tools to examine MF as a surrogate end point in clinical trials and as a therapeutic target for established and emerging novel therapeutics.
Emerging Applications for Novel Therapeutic Development and Clinical Trial End Points:
The Big Picture of Thinking Small
Identifying the involvement of a particular myocardial compartment in heart disease establishes a potential role of heart in the paradigms of cardiac syndromes, for example, heart failure. Importantly, myocardial compartmental involvement specifies the cellular/molecular disease pathways located in the heart for targeted pharmaceutical development. This ability remains important because the central role of the heart has been challenged in heart failure, especially in the setting of preserved ejection fraction. [3] [4] [5] We note that MF measures associate with vulnerability to adverse events across the spectrum of ejection fraction and heart failure stage. This observation elevates the importance of MF compared with other concurrent derangements and suggests that MF may mediate outcomes as a causal factor.
Instead of characterizing the myocardium as a homogeneous contractile tissue and using important yet still generic descriptors, such as thickness (hypertrophy), and function (diastolic or systolic function), all of which lack mechanistic specificity, paradigms of cardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on the extent of disease involving its various compartments. 6, 105, 106 These compartments include the following:
-The myocardial interstitium containing the extracellular matrix typically regulated by fibroblasts, which can transform into synthetically active myofibroblasts after stimulation by neurohormonal, paracrine, and other factors; 1 -The cardiomyocyte, which can hypertrophy in response to hemodynamic loading factors; 1 -The microvasculature also embedded within the interstitium and affected by interstitial expansion.
14 Partitioning the myocardium into its distinct myocardial compartments crystallizes a fundamental concept: specifying the particular cellular and molecular disease pathways that underlie generic measures of dysfunction. Weber and Brilla 1 articulated this important concept decades ago. This crucial knowledge of the involved cellular and molecular disease pathways can then foster targeted therapeutics (ie, personalized medicine) and accelerate the challenging task of pharmacological development.
An extension of this concept of myocardial compartments is that patient vulnerability may relate more to myocardial quality (ie, extent of excess interstitial expansion, usually from MF) than quantity (left ventricular mass). 105, 107 ECV measures the volume percent of the interstitial compartment, which represents a well-validated surrogate of MF in most settings. [23] [24] [25] 29, [33] [34] [35] [36] Similarly, CMR can measure the cardiomyocyte compartment (ie, 100%−ECV) to gauge cardiomyocyte hypertrophy in the context of increased total left ventricular mass measures. At the macroscopic level, left ventricular hypertrophy may be adaptive or maladaptive. 1 ECV data indicate that expansion of the interstitial compartment by MF seems to be the key distinction between adaptive and maladaptive hypertrophy of the left ventricle, as articulated decades ago. 1 Indeed, ECV measurement may distinguish the adaptive hypertrophy in athletic heart from other pathological hypertrophy seen in other disease states. 108 This concept of equating MF with vulnerability is further supported by associating ECV with outcomes. [7] [8] [9] [10] [11] [12] [13] 89 In fact, ECV demonstrates added prognostic value beyond several other established risk factors using rigorous contemporary statistical metrics (eg, net reclassification improvement and integrated discrimination improvement). 7 Outcomes data reveal a clear dose-response relationship between ECV and prognosis ( Figure 2 ) that suggests the potential for causality. These outcomes data represent a crucial component of the concept that MF is a legitimate therapeutic target, worthy of investing the requisite resources needed for the development of antifibrotic drugs. Because of limited availability of CMR, the cardiology community requires biomarkers to identify MF-enriched populations without reliance on CMR, perhaps with phenomapping approaches 109 or plasma biomarker profiles. 110 These populations would be then targeted to investigate agents that prevent or reverse MF.
Emerging Applications: Targeting MF in Randomized Controlled Trials
Given MF-outcomes associations and the reversibility of MF-pathophysiology associations noted above, it follows that modestly efficacious antifibrotic treatment with RAAS inhibition would prove efficacious in large randomized phase 3 trials. Indeed, trials of RAAS inhibition targeting heart failure with reduced ejection fraction proved successful. RAAS inhibition may also be useful in patients with heart failure with preserved ejection fraction (HFpEF), but this concept is less well established.
To date, HFpEF trials may have been hindered by several factors including (1) methodologic problems (eg, high crossover rates between treatment arms, 111 high background treatment with other RAAS inhibitors, 112, 113 or poor protocol compliance diluting potential therapeutic impact 114 ), (2) greater disease heterogeneity in HFpEF, whereby HFpEF occurs from cardiac and noncardiac derangements that do not necessarily involve MF, 115 and (3) limited efficacy of RAAS inhibition where the collagen volume fraction regresses in humans by only ≈20% relative change and 1% absolute change over ≈10 months (Table 2) . [14] [15] [16] [17] 74 While the burden of MF in ECV for Novel Therapeutics heart failure with reduced ejection fraction and HFpEF may be similar, 116 the prevalence of MF in HFpEF most likely varies with disease severity, the degree of associated profibrotic comorbidity (eg, diabetes mellitus 8 ), and the exact definition used to designate HFpEF. Similarly, the treatment benefit of antifibrotic treatment with RAAS inhibition or other emerging efficacious antifibrotic medications 85, 117 may vary with extent of underlying MF.
HFpEF trials may resemble hypertension trials. Comorbidity and disease severity may vary so greatly in HFpEF that the treatment benefits of RAAS inhibition may depend on whether the baseline comorbidity and risk for MF is low or high. Indeed, the HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) of candesartan in lower risk individuals without cardiovascular disease (ie, no left ventricular hypertrophy with low prevalence of diabetes mellitus [6%] which promotes MF 8 ) was neutral. 118 Yet, the LIFE trial (Losartan Intervention for Endpoint Reduction) of losartan where all participants had left ventricular hypertrophy and the diabetes mellitus prevalence was higher (12%) yielded positive results. 119 Similarly, the first HOPE trial 120 also yielded positive results with ramipril in a population with preserved ejection fraction, where the prevalence of myocardial infarction and coronary disease (known stimuli for MF 18, 96 ) was high. For future phase 2 and 3 trials, ECV provides a precise tool to gauge MF severity, risk of adverse events and, therefore, Industry and the cardiology community require phase 2 trials evaluating the specific treatment of MF. Presently, diagnostics have advanced more than therapeutics. Clinicians need to understand how to treat MF. MF is (1) prevalent, 7 (2) associated with other parameters of cardiac dysfunction through relatively specific collagen-cardiomyocyte interactions, (3) strongly associated with outcomes, apparently more so than even ejection fraction and myocardial infarction, 7 and (4) reversible. It seems likely then that drugs with high anti-MF efficacy in phase 2 trials may yield positive results in phase 3. For example, serelaxin is a potent antifibrotic medication 85 (among many other biological effects) that yielded surprisingly favorable results on mortality in the RELAX-HF trial (Serelaxin, Recombinant Human Relaxin-2, for Treatment of Acute Heart Failure). 118 Antifibrotic medications possibly more potent than RAAS inhibition are under development. 85, 86, 121, 122 This MF-centric strategy of therapeutic development might reverse the series of neutral trials over the past decade that have challenged the heart failure community. 116, 123 The conceptual model of using ECV measures of MF to foster novel therapeutics is illustrated in Figure 3 .
Statistical Appraisal of ECV Measures of MF in Observational Data
Strong associations between ECV MF measures and baseline disease severity metrics and then subsequent outcomes support inferences of causality. Yet, establishing causality ultimately requires randomized blinded phase 2 trials first to show efficacy of antifibrotic agents regressing fibrosis and then phase 3 trials to show risk reduction for adverse events with antifibrotic treatment. Several pitfalls may occur when interpreting observational ECV data using risk adjustment. When appraising associations between predictor variables and outcomes, it is useful to consider whether predictor variables reflect specific disease pathways or generalized disease. Summary disease severity measures (eg, B-type natriuretic peptide) can reflect multiple disease pathways (including MF and other pathways) and may capture the overall integrated risk to the patient, but they do not illuminate the underlying cause(s) or the magnitude of their contribution to risk. The nonspecificity of generic disease severity variables provides an intrinsic advantage for predicting outcomes because they may summarize multiple important disease pathways rather than a singular pathway. They may indicate a need for treatment, but cannot specify which treatment without additional knowledge. It may be more useful to adjust for covariates that specify distinct underlying pathophysiologic derangements rather than generic overall risk. This approach enables comparison of the contributions to patient risk by various distinct pathophysiologic pathways. The conceptual model of using extracellular volume (ECV) measures of MF to foster novel therapeutics: MF develops after various exposures that culminate in disruption of normal collagen homeostasis, detectable by ECV. MF confers vulnerability through various interactions listed in the red text box, but these seem reversible, illustrating dysfunctional but viable and salvageable myocardium. Indeed, dysfunctional myocardium often may be salvageable in the absence of large amounts of focal myocardial scarring, and some think there is enormous, untapped cardiac reserve in most hearts. The extent to which conventional (eg, mineralocorticoid receptor antagonists) and novel antifibrotic agents regress myocardial fibrosis, improve function, and improve outcomes requires further study in phase 2 and 3 clinical trials, respectively. ECV for Novel Therapeutics
In multivariable statistical models, loss of statistically significant association between ECV MF measures and an outcome may simply suggest that other disease processes may be more prevalent. Undoubtedly, many pathways of disease can lead to adverse cardiac outcomes. 124 Knowledge of the baseline distribution of ECV in the study population may help interpretation of results. Clearly, lower prevalence of MF in populations increases the challenge of demonstrating associations in multivariable models as do smaller sample sizes and lower numbers of events. In addition, loss of statistically significant association between ECV MF measures and an outcome also may suggest underlying collinearity and interactions between ECV and other disease severity measures, which serve to diminish the associations between ECV and outcomes.
Conclusions
Quantifying MF with routine myocardial ECV measures acquired during CMR introduces an exciting era in cardiology that ultimately promises to transform clinical care by advancing pathophysiologic understanding and fostering novel therapeutics. MF represents pathological remodeling in the heart 1, 2 that is associated with cardiac dysfunction 11, [13] [14] [15] [16] [17] 44, 72, 125 through interactions with other compartments (eg, the myocardial microvasculature, cardiomyocytes). As such, MF is associated with adverse outcomes. [7] [8] [9] [10] [11] [12] [13] Reversal of MF improves key domains cardiac dysfunction parameters, [14] [15] [16] [17] [18] establishing that the myocardium remains viable and salvageable, and so reversal of MF represents a likely mechanism for improved outcomes as well. 19 Instead of characterizing the myocardium as a homogenous contractile tissue and using important yet still generic descriptors such as thickness (hypertrophy) and function (diastolic or systolic function), all of which lack mechanistic specificity, paradigms of cardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on the extent of disease involving its various compartments. 6, 105, 106 Specification of the myocardial compartments involved in myocardial disease (eg, extracellular compartment expansion from MF) in turn identifies cellular/molecular disease pathways for targeted pharmaceutical development. To translate discoveries into improved patient care, the cardiology community now requires phase 2 and 3 trials examining strategies for the regression/prevention of MF and eventually biomarkers to identify MF without reliance on CMR.
